Agilent Expands Cell Analysis R&D Capabilities in Ireland
November 16 2018 - 11:00AM
Business Wire
New facility incorporates recently acquired Luxcel
Biosciences
Agilent Technologies Inc. (NYSE: A) today announced the opening
of a new, purpose-built extension to its Little Island, Cork
facility in Ireland. The campus will focus on developing advanced
technologies for the analysis of live-cells in real-time.
The expanded state-of-the-art facility incorporates recently
acquired Luxcel Biosciences, adding real-time, fluorescence plate
reader-based in vitro cell assay kits to Agilent’s cell analysis
portfolio. The complex will house two new laboratories, one
dedicated to cell analysis technologies, and the other to develop
biosensors and related bio assay solutions.
Agilent entered the cell analysis market in 2015 with the
acquisition of Seahorse Bioscience, a leader in the development of
specialized instruments and live-cell, kinetic assays. The addition
of Luxcel expands Agilent's cell analysis portfolio and brings new
capabilities through technology and research which will drive
advancements in this fast-evolving field for Agilent globally.
“Technological progression allowing researchers to examine cell
health and function kinetically, and in real-time, are driving
global demand for complete cell analysis solutions,” said Todd
Christian, general manager, Agilent Cell Analysis Division. “The
Luxcel acquisition and Agilent Ireland expansion underscore
Agilent’s continued commitment to the growing cell analysis
market.”
“We’re excited that Agilent has invested in Ireland,” said
Martin Shanahan, chief executive officer, IDA Ireland. “Luxcel has
partnerships and active research programs in Ireland, and with
major EU and UK research institutions. This expansion will not only
provide the most up-to-date and advanced solutions for Agilent’s
customers but will have a significant positive impact within the
Irish and European innovation ecosystem.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.47 billion in fiscal 2017 and employs 14,500 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
our Newsroom. Follow Agilent on LinkedIn, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181116005009/en/
Victoria Wadsworth-HansenAgilent Technologies+1 408 553 2005+45
2933 6980victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024